drugset / Trial / NCT04825652
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
Summary
The purpose of this Cohort Treatment Plan is to allow access to 177Lu-PSMA-617 for eligible patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC). The patient's treating physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-PSMA-617 | Other / unclassified | 7400 mbq | — |
| Subject | PSMA-11 | Diagnostic / imaging agent | 1.8 mbq/kg | — |
| Subject | PSMA-11 | Diagnostic / imaging agent | 2.2 mbq/kg | — |
| Subject | PSMA-11 | Diagnostic / imaging agent | 111 mbq | — |
| Subject | PSMA-11 | Diagnostic / imaging agent | 259 mbq | — |